

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 13, 2015**

---

**KURA ONCOLOGY, INC.**  
(Exact name of Registrant as Specified in Its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-53058**  
(Commission  
File Number)

**61-1547851**  
(IRS Employer  
Identification No.)

**11119 N. Torrey Pines Road, Suite 125, La Jolla, CA**  
(Address of Principal Executive Offices)

**92037**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (858) 500-8800**

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On October 13, 2015, the Board of Directors (the “Board”) of Kura Oncology, Inc. (the “Company”) appointed Thomas Malley as a director of the Company, with a term of office expiring at the next annual meeting of stockholders. There are no arrangements or understandings between Mr. Malley and any other person pursuant to which he was selected as a director. In addition, there are no transactions in which Mr. Malley has an interest that would require disclosure under Item 404(a) of Regulation S-K.

Pursuant to the Company’s standard compensation policy for non-employee directors, Mr. Malley will receive an annual cash retainer of \$50,000, and was granted an option to purchase 30,000 shares of the Company’s common stock at the fair market value on the date of his appointment, which vests annually over a three year period with vesting acceleration in the event of a change in control (as defined in the Company’s equity incentive plan) during the period of Board service. Mr. Malley has also entered into the Company’s standard form of Indemnification Agreement.

The Company issued a press release announcing the appointment of Mr. Malley, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

*(d) Exhibits*

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release issued by Kura Oncology, Inc. on October 14, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 14, 2015

**KURA ONCOLOGY, INC.**

By: /s/ Annette North

Annette North

Senior Vice President and General Counsel



## **Kura Oncology Appoints Thomas Malley to Board of Directors**

**LA JOLLA, Calif., October 14, 2015** – Kura Oncology, Inc. (OTCQB: KURO), a clinical stage biopharmaceutical company, today announced the appointment of Thomas Malley to its board of directors.

“Tom has extensive knowledge and understanding of the healthcare industry,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “I am confident his skills and experience will be invaluable as we seek to advance our pipeline of precision medicines for the treatment of solid tumors and blood cancers.”

Mr. Malley has served as President of Mossrock Capital, LLC, a private investment firm, since May 2007. He worked for Janus Mutual Funds in positions of increasing responsibility from April 1991 to May 2007. From January 1999 to May 2007, Mr. Malley served as the portfolio manager of the Janus Global Life Sciences Fund, and also led the Janus Healthcare team of analysts. From 1991 to 1998, Mr. Malley served as an equity analyst for Janus covering, among others, healthcare and biotechnology stocks. Mr. Malley has been a director of OvaScience, Inc., a public life sciences company, since October 2012. Previously, he served as a director of Synageva BioPharma Corp., a public biopharmaceutical company, from 2006 to 2015, until its acquisition by Alexion Pharmaceuticals, Inc., Puma Biotechnology, Inc., a public biopharmaceutical company, from 2011 to 2015, and Cougar Biotechnology, Inc., a public biopharmaceutical company, from 2007 to 2009, until its acquisition by Johnson and Johnson. Mr. Malley holds a B.S. in Biology from Stanford University.

### **About Kura Oncology**

Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura’s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The company’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor currently in two Phase 2 clinical studies: the first in patients with locally advanced tumors that carry HRAS mutations and the second in patients with peripheral T-cell lymphoma. The company’s preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL inhibitor program.

### **CONTACT INFORMATION**

#### **INVESTOR CONTACT:**

Robert H. Uhl  
Managing Director  
Westwicke Partners, LLC  
(858) 356-5932

**MEDIA CONTACT:**  
Mark Corbae  
Vice President  
Canale Communications  
(619) 849 5375  
[mark@canalecomm.com](mailto:mark@canalecomm.com)